ARTICLE | Clinical News
PF-05280014: Ph III REFLECTIONS B3271002 trial
December 7, 2016 10:28 PM UTC
Top-line data from the double-blind, international Phase III REFLECTIONS B3271002 trial in 690 patients with HER2-positive metastatic breast cancer showed that first-line treatment with PF-05280014 pl...
BCIQ Company Profiles
BCIQ Target Profiles
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)